Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
56.24M | 56.13M | 79.18M | 73.67M | 63.13M | 44.53M | Gross Profit |
37.39M | 35.26M | 52.52M | 42.89M | 31.05M | 29.94M | EBIT |
-6.91M | -13.68M | -2.07M | -27.52M | -25.34M | 7.85M | EBITDA |
-1.43M | -8.40M | 1.92M | -23.18M | -32.77M | 9.37M | Net Income Common Stockholders |
-8.30M | -14.67M | -3.85M | -29.63M | -43.99M | 5.28M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
21.07M | 20.30M | 27.44M | 32.00M | 49.08M | 8.25M | Total Assets |
84.96M | 80.24M | 76.85M | 105.16M | 97.28M | 51.91M | Total Debt |
25.17M | 25.08M | 17.73M | 22.96M | 910.00K | 5.40M | Net Debt |
4.10M | 4.78M | -9.71M | -9.04M | -48.17M | -2.84M | Total Liabilities |
63.42M | 60.17M | 56.50M | 88.18M | 55.24M | 41.61M | Stockholders Equity |
21.54M | 20.07M | 20.35M | 16.98M | 42.04M | 10.29M |
Cash Flow | Free Cash Flow | ||||
-21.94M | -9.13M | 240.00K | -33.53M | -12.18M | 3.93M | Operating Cash Flow |
-6.94M | -9.13M | 5.24M | -13.53M | -2.18M | 5.13M | Investing Cash Flow |
-15.00M | -15.00M | -5.00M | -20.00M | -10.00M | -1.20M | Financing Cash Flow |
18.95M | 16.99M | -4.80M | 16.46M | 53.02M | -487.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $65.08M | ― | -11.67% | ― | 5.82% | 59.86% | |
51 Neutral | $7.34B | 0.29 | -60.38% | 2.38% | 17.46% | 1.71% | |
51 Neutral | $151.66M | ― | -48.14% | ― | -29.69% | -105.88% | |
50 Neutral | $212.07M | ― | 23.44% | ― | 12.99% | 17.78% | |
50 Neutral | $97.22M | ― | 75.79% | ― | 10.58% | 34.44% | |
46 Neutral | $113.53M | 85.74 | -8.02% | ― | -23.18% | 97.12% | |
33 Underperform | $155.59M | ― | -30.20% | ― | ― | ― |
On April 1, 2025, Journey Medical Corporation appointed Ramsey Alloush as Chief Operating Officer while he continues as General Counsel. Alloush, who joined the company in 2020, has played a significant role in its growth and strategic initiatives, including leading the IPO in 2021. His appointment comes at a pivotal time as the company prepares to launch Emrosi™, a new dermatological treatment expected to drive the company’s growth and redefine market standards.